Sinopharm sees revenue and profit decline in first half 2025

Sinopharm Group Co. Ltd. reported revenue of RMB286,043.00m for the six months ended 30 June 2025, a 2.95% decrease from RMB294,726.81m in the same period of 2024. Net profit for the period fell by 9.53% to RMB5,337.25m, with profit attributable to owners of the parent decreasing by 6.43% to RMB3,465.69m. Basic earnings per share were RMB1.11, down 6.72% from the prior year.

The pharmaceutical distribution segment's revenue decreased by 3.52% to RMB218,527.36m, while medical device distribution revenue declined by 2.46% to RMB57,052.73m. In contrast, the retail pharmacy segment showed growth, with revenue increasing by 3.65% to RMB17,162.12m.

Despite the revenue challenges, the group demonstrated effective expense control, with the selling expense ratio, administrative expense ratio, and financial expense ratio all decreasing. Cash and cash equivalents stood at RMB35,238.14m as of 30 June 2025, down from RMB54,313.36m at the end of 2024. The gearing ratio increased to 69.25% from 67.75%.